Citigroup
RCEL icon

Citigroup’s Avita Medical RCEL Stock Holding History

Citigroup’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73K Buy
738
+462
+167% +$1.94K ﹤0.01% 5379
2025
Q4 		$952 Sell
276
-241
-47% -$962 ﹤0.01% 5548
2025
Q3 		$2.64K Sell
517
-8,917
-95% -$46.5K ﹤0.01% 5412
2025
Q2 		$49.9K Sell
9,434
-9,105
-49% -$66.2K ﹤0.01% 4754
2025
Q1 		$151K Sell
18,539
-1,987
-10% -$18.6K ﹤0.01% 4353
2024
Q4 		$263K Buy
20,526
+2,081
+11% +$24.5K ﹤0.01% 4240
2024
Q3 		$198K Buy
18,445
+11,570
+168% +$109K ﹤0.01% 4351
2024
Q2 		$54.5K Sell
6,875
-40,111
-85% -$382K ﹤0.01% 4527
2024
Q1 		$753K Buy
46,986
+43,428
+1,221% +$703K ﹤0.01% 3254
2023
Q4 		$48.8K Buy
3,558
+3,543
+23,620% +$40.6K ﹤0.01% 4534
2023
Q3 		$219 Sell
15
-7,472
-100% -$126K ﹤0.01% 5311
2023
Q2 		$127K Sell
7,487
-32,659
-81% -$479K ﹤0.01% 4119
2023
Q1 		$561K Buy
40,146
+19,067
+90% +$203K ﹤0.01% 3039
2022
Q4 		$139K Buy
+21,079
New +$126K ﹤0.01% 3890
2022
Q3 		– Sell
-373
Closed -$2K – 6234
2022
Q2 		$2K Sell
373
-501
-57% -$3.1K ﹤0.01% 5911
2022
Q1 		$7K Sell
874
-32,170
-97% -$296K ﹤0.01% 5701
2021
Q4 		$396K Buy
33,044
+17,867
+118% +$272K ﹤0.01% 3947
2021
Q3 		$269K Sell
15,177
-26,849
-64% -$507K ﹤0.01% 3965
2021
Q2 		$862K Buy
42,026
+6,441
+18% +$127K ﹤0.01% 3343
2021
Q1 		$705K Buy
35,585
+35,516
+51,472% +$826K ﹤0.01% 3224
2020
Q4 		$1K Buy
69
+19
+38% +$417 ﹤0.01% 7291
2020
Q3 		$1K Hold
50
– – ﹤0.01% 7379
2020
Q2 		$2K Hold
50
– – ﹤0.01% 7420
2020
Q1 		$2K Hold
50
– – ﹤0.01% 7440
2019
Q4 		$2K Buy
+50
New +$2.08K ﹤0.01% 7558

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's RCEL Position: Q1 2026 in Review

Citigroup increased its Avita Medical (RCEL) stake by 167% in Q1 2026, buying an estimated $1.94K and bringing the position to 738 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #5379.

Citigroup first reported a position in RCEL in Q4 2019 and has held it in 25 quarters since. The position peaked at $862K in Q2 2021. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Citigroup held 738 shares of Avita Medical worth $2.73K as of Q1 2026.
  • Citigroup bought 462 Avita Medical shares in Q1 2026, an estimated $1.94K.
  • Avita Medical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5379 holding.
  • Citigroup first reported a position in Avita Medical in Q4 2019 and has held it in 25 quarters since.
  • Citigroup's Avita Medical position peaked at $862K in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.